Enhanced Recovery After Surgery (ERAS) in Surgical Oncology
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
PURPOSE OF THE REVIEW: The objective of this review is to address the rationale behind the application of the Enhanced Recovery After Surgery (ERAS) protocols that could improve oncologic outcomes in adult patients undergoing major surgery.
RECENT FINDINGS: The implementation of ERAS protocols has been associated with fewer postoperative complications as well as decreased return to intended oncologic treatment (RIOT). However, few studies have analyzed the influence of the application of ERAS protocols and long-term oncologic outcomes, although some of its individual elements have been associated with improvements in oncologic outcomes, including overall survival and disease-free survival. Targeted long-term follow-up studies in specific oncologic procedures are required to determine whether ERAS application results in improved oncologic outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Current oncology reports - 24(2022), 9 vom: 11. Sept., Seite 1177-1187 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ripollés-Melchor, Javier [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.09.2022 Date Revised 12.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11912-022-01282-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339335912 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339335912 | ||
| 003 | DE-627 | ||
| 005 | 20231226002654.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11912-022-01282-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1131.xml |
| 035 | |a (DE-627)NLM339335912 | ||
| 035 | |a (NLM)35403970 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ripollés-Melchor, Javier |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhanced Recovery After Surgery (ERAS) in Surgical Oncology |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.09.2022 | ||
| 500 | |a Date Revised 12.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a PURPOSE OF THE REVIEW: The objective of this review is to address the rationale behind the application of the Enhanced Recovery After Surgery (ERAS) protocols that could improve oncologic outcomes in adult patients undergoing major surgery | ||
| 520 | |a RECENT FINDINGS: The implementation of ERAS protocols has been associated with fewer postoperative complications as well as decreased return to intended oncologic treatment (RIOT). However, few studies have analyzed the influence of the application of ERAS protocols and long-term oncologic outcomes, although some of its individual elements have been associated with improvements in oncologic outcomes, including overall survival and disease-free survival. Targeted long-term follow-up studies in specific oncologic procedures are required to determine whether ERAS application results in improved oncologic outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adenocarcinoma/surgery | |
| 650 | 4 | |a Analgesia*/mortality | |
| 650 | 4 | |a Anesthesia, conduction/adverse effects | |
| 650 | 4 | |a Colonic neoplasms/pathology | |
| 650 | 4 | |a Colonic neoplasms/surgery | |
| 650 | 4 | |a Disease progression | |
| 650 | 4 | |a Disease-free survival | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Laparoscopy | |
| 650 | 4 | |a Neoplasm recurrence, local/mortality | |
| 650 | 4 | |a Neoplasm recurrence, local/prevention and control | |
| 650 | 4 | |a Neoplasm staging | |
| 650 | 4 | |a Neoplasms/immunology | |
| 650 | 4 | |a Neoplasms/mortality | |
| 650 | 4 | |a Survival analysis | |
| 650 | 4 | |a Treatment outcome | |
| 700 | 1 | |a Abad-Motos, Ane |e verfasserin |4 aut | |
| 700 | 1 | |a Zorrilla-Vaca, Andrés |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current oncology reports |d 1999 |g 24(2022), 9 vom: 11. Sept., Seite 1177-1187 |w (DE-627)NLM110371534 |x 1534-6269 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2022 |g number:9 |g day:11 |g month:09 |g pages:1177-1187 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11912-022-01282-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2022 |e 9 |b 11 |c 09 |h 1177-1187 | ||